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population, with an estimated prevalence in the adult pop-
ulation of 4% as detected by palpation, 50% as detected at
autopsy, and as high as 67% as detected by ultrasonography
[1]. We can reasonably conclude that millions of Canadians
have thyroid nodules, the vast majority of which are impal-
pable. With the widespread use of medical imaging, many of
these nodules, some as small as 2e3 mm in diameter are
detected incidentally when patients undergo imaging studies
of the neck, often for reasons unrelated to the thyroid gland,
hence the descriptor ‘‘thyroid incidentalomas.’’ Unless
a nonpalpable thyroid nodule is causing thyrotoxicosis, its
clinical significance derives from the possibility that it is an
occult cancer [2]. It is thought that approximately 9%13%
of thyroid nodules, whether palpable or nonpalpable, single
or multiple, are cancers [3,4]. Most of these are well-
differentiated papillary carcinomas, the most common
subtype of thyroid cancer.
In contrast to occult disease, clinically apparent thyroid
cancer is not common, nor is it usually aggressive. The most
recent Canadian cancer statistics estimate a 2.5% incidence
of thyroid cancer in 2008, with an estimated 0.23% of all
cancer deaths from this neoplasm [5]. Of the 17 types of
cancer reported upon, thyroid cancer has the highest esti-
mated 5-year survival ratio of 98%. The same document
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standardized mortality rate, a phenomenon that the investi-
gators acknowledge is likely because of the more frequent
use of medical imaging that leads to the detection of small
subclinical differentiated tumours [6]. Davies and Welch [7],
in their analysis of American data, similarly concluded that
the rising incidence of thyroid cancer in the United States is
attributable to increased detection of small, 10e20 mm,
papillary cancers that result from increased diagnostic scru-
tiny, an apparent rather than a real increase in cancer
incidence.
Another study from the United States showed an associ-
ation between thyroid cancer incidence and socioeconomic
indicators of health care access, which supports the
hypothesis that the rising incidence is attributable to uti-
lisation of new diagnostic practices rather than any real
change in the epidemiology of the disease [8]. Similar trends
were reported from France and Germany [9,10]. All of these
reports are highly suggestive of overdiagnosis or the detec-
tion of pseudodisease. The management of this iatrogenic
epidemic of thyroid nodules has been described by 1 endo-
crinologist as ‘‘the ignorant in pursuit of the impalpable’’
[11].
Autopsy studies confirm that clinically undetected thyroid
cancer has a much higher prevalence than that of clinical
cancer. Two such studies, 1 from Finland and 1 from Spain,
demonstrated that, when the thyroid glands of persons not
known to have had thyroid cancer during their lifetime were
sliced into 2e3-mm blocks, 1 or more foci of occult cancer,
usually of papillary origin, were detected in 36% and 22% of
glands, respectively [12,13]. Harach et al [12] calculatedll rights reserved.
Table 1
Recommendation for thyroid nodules 1 cm or larger in maximum diameter
(modified from Frates et al [4])*
US feature Recommendation
Solitary nodule
Microcalcifications Strongly consider FNA if 1 cm
Solid (or almost entirely solid)
or coarse calcifications
Strongly consider FNA
if 1.5 cm
Mixed solid and cystic or almost
entirely cystic with solid mural
component
Consider FNA if 2 cm
None of the above but substantial
growth since prior US examination
Consider FNA
Almost entirely cystic and none
of the above and no substantial
growth (or no prior US)
FNA probably unnecessary
Multiple nodules Consider FNA of one or more
nodules, with selection
prioritized on basis of
criteria for solitary nodule
US ¼ ultrasonography; FNA ¼ fine needle aspiration.
*In the presence of abnormal cervical lymph nodes, FNA of the node and/
or the ipsilateral thyroid nodule is recommended.
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person’s thyroid gland would be found to contain occult
papillary thyroid cancer. Martinez-Tello et al [13] reasoned
that most occult papillary cancers regress and that only
a small number evolve into clinical cancer. Thus, there is
a large reservoir of subclinical thyroid cancer in the general
population, which, because of the widespread dissemination
of sophisticated medical imaging technology, we now have
the ability to detect.
Although it is recognized that most occult differentiated
thyroid carcinomas will follow an indolent course, there are
case reports from around the world of small impalpable
thyroid cancers that presented with distant metastases. This
has placed pressure upon physicians to investigate such
nodules with ultrasound-guided fine needle aspiration (FNA).
Determining when a nodule should be selected for biopsy is
controversial. The work of Papini et al [14], which recom-
mends FNA of all 8e15 mm nodules with ‘‘irregular
margins, intranodal vascular spots, or microcalcification,’’
has been influential in guiding clinical management.
However, in the application of these and other sonographic
characteristics reported to be predictive of thyroid cancer,
Iannuccilli et al [15] concluded that only intrinsic micro-
calcification was a statistically significant predictor of
malignancy. Moon et al [16] attributed the lack of reliability
in the distinction of benign from malignant thyroid nodules
based upon sonographic features to
 considerable overlap in their morphology,
 the variable experience of physicians interpreting
ultrasound,
 technical variation in ultrasound scanners,
 the lack of a standard lexicon for the characterization of
nodules.
For these reasons, the size of the nodule as determined by
its largest diameter has become a widely used criterion for
determining the need for FNA. In a recent publication,
Bonavita et al [17] described 4 ultrasound patterns, which in
their practice had a 100% specificity for benignity and could
have obviated the need for up to 60% of biopsies. This
promising observation needs to be confirmed by other
workers.
The American Association of Clinical Endocrinologists
(AACE), the American Thyroid Association, and the Society
of Radiologists in Ultrasound (SRU) have each published
practice guidelines to assist clinicians in deciding when to
biopsy nonpalpable thyroid nodules [3,4,18]. Although there
is discordance among the guidelines regarding the approach
to 10-14-mm nodules, all 3 set the threshold for FNA at 10
mm in patients at low risk for thyroid cancer. The SRU
guidelines are the most stringent in that a 10-mm threshold
applies only if the nodule contains microcalcification
(Table 1). McCartney and Stukenborg [19] designed a deci-
sion analysis that compares all 3 guidelines, in which the
uncertain risk of delaying surgery when cancer is present was
balanced with the well-defined risks of undergoing surgeryfor a benign asymptomatic nodule. The investigators
concluded that the AACE and SRU guidelines have the best
performances, depending upon which outcome is considered
the less desirable: undergoing unnecessary surgery for
a benign nodule or missing an early malignancy. The SRU
guidelines are associated with a lower rate of surgery for
benign disease, whereas the AACE guidelines yield a lower
risk of missed malignancy.
The detection of cancer cells or cells with suspicious
cytologic features after FNA regardless of the size of the
nodule typically leads to total or partial thyroidectomy. If the
excised lesion is confirmed to be malignant on histologic
analysis, then adjunct radioactive iodine ablation is often
performed. However, there is a substantial false positive rate
associated with the cytologic assessment of thyroid nodules.
Yang et al [20], reporting on 4703 FNA samples, noted that,
whereas the cytologic finding of ‘‘positive for neoplasm’’
was 98.6% predictive of histologically confirmed malig-
nancy, the cytologic diagnosis of ‘‘follicular neoplasm’’
(which typically leads to thyroid resection) was only 32.2%
predictive of malignancy. Patients undergoing treatment face
the risks of thyroid surgery and perhaps a lifetime of thyroid
replacement therapy and medical surveillance. They require
the resources of endocrinologists, radiologists, pathologists,
anesthesiologists, surgeons, nuclear medicine physicians,
and various allied health professionals.
Current practice guidelines recommending FNA of small
impalpable nodules create a de facto case-based screening
program for a disease that, because of its low morbidity and
mortality, meets none of the standard epidemiologic criteria
to warrant population-based screening. Can the aggressive
pursuit of occult thyroid nodules be justified in Canada when
it is widely publicized that we are unable to provide timely
care for large numbers of our citizens with a host of
clinically apparent diseases? Our national cancer experts
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although the rising incidence of thyroid cancer is likely an
apparent rather than a real increase, more vigilance is called
for in the detection of these cancers because of this same
rising incidence [5]. Their advice, if followed, will lead us
into the futile cycle of increasing intervention without
evidence of any population benefit [21]. It is clear that we
need to gain more knowledge of the natural history of
impalpable thyroid cancer, but, given the widespread
dissemination of guidelines calling for FNA of small non-
palpable nodules, it is unlikely that a large randomized trial
of watchful waiting vs definitive treatment will be imple-
mented. It is interesting to note that, in a Japanese study of
162 patients with papillary microcarcinoma diagnosed by
using FNA and who chose close observation rather than
immediate surgery, 70% of the nodules either did not enlarge
or decreased in size at a mean follow-up of 46 months [22]. It
is also relevant to remember that overt differentiated papil-
lary thyroid cancer, in particular, remains an often effectively
treatable condition even when it has metastasized. Thus, the
usual, if questionable, paradigm of equating the probability
of cure with early diagnosis may not be valid in this
circumstance.
Canada’s approach to health care allocation most closely
conforms to the World Medical Association models of util-
itarianism, or distribution according to maximal benefit for
all, and egalitarianism, or distribution according to need [23].
The utilitarian model is, in turn, based on the principle of
merit, defined as the potential for individuals in society to
benefit from the allocation of a resource [24]. We now have
evidence that our increasingly aggressive approach to the
detection of impalpable thyroid cancers has not altered the
mortality rate from thyroid cancer from that era of a few
decades ago in which only palpable cancers could be
detected. As questioned provocatively in this context by
Cronan [25], ‘‘is it time to turn off the ultrasound
machines?’’
Although such a course is unlikely, physicians who order
and/or perform thyroid ultrasonography should engage in
discussion both together and with patients over the merits of
the aggressive pursuit of thyroid incidentalomas. In those
persons discovered to have incidental nonpalpable thyroid
nodules who have no clinical risk factors for thyroid cancer
and no evidence of metastases, an automatic referral for FNA
may not be appropriate. Individuals who are sent for FNA of
subclinical impalpable thyroid nodules need to be provided
with adequate information about the path upon which they
are embarking. This information should include the known
physical and psychological risks of treatment should their
biopsy specimen demonstrate cancer cells, the possibility
that they might ultimately undergo unnecessary thyroidec-
tomy for benign disease, and a statement regarding the
uncertain benefits from the treatment of potentially indolent
thyroid cancer. The periodic observation of impalpable
thyroid nodules in otherwise asymptomatic patients is
a rational course of action [11]. In those situations in which it
is deemed appropriate to proceed to FNA, the SRUguidelines would seem to be the most appropriate to apply in
the Canadian context, in which medical resources are
severely strained and our emphasis should be biased towards
preventing unnecessary surgery for benign disease.References
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